Abstract | PURPOSE OF REVIEW: RECENT FINDINGS: SUMMARY: The unfavorable risk:benefit ratio of high-dose dexamethasone suggests that it should not be routinely prescribed for dyspnea in cancer patients. More research is needed to assess the selective use of corticosteroids and identify patients most likely be benefit from corticosteroid use.
|
Authors | David Hui, Sriram Yennurajalingam |
Journal | Current opinion in supportive and palliative care
(Curr Opin Support Palliat Care)
Vol. 17
Issue 4
Pg. 270-276
(12 01 2023)
ISSN: 1751-4266 [Electronic] United States |
PMID | 37773042
(Publication Type: Review, Journal Article, Research Support, Non-U.S. Gov't, Research Support, N.I.H., Extramural)
|
Copyright | Copyright © 2023 Wolters Kluwer Health, Inc. All rights reserved. |
Chemical References |
- Dexamethasone
- Adrenal Cortex Hormones
|
Topics |
- Humans
- Dexamethasone
(therapeutic use)
- Pilot Projects
- Vena Cava, Superior
- Adrenal Cortex Hormones
(adverse effects)
- Neoplasms
(complications, drug therapy)
- Dyspnea
(drug therapy, etiology)
- Randomized Controlled Trials as Topic
|